Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cardiovascular & Hematological Disorders Drug Targets|December 31, 2016
Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al OverviewMilunovic Vibor, Inga Mandac Rogulj, Slobodanka Kolonic Ostojic
Journal of Hematology & Oncology|August 15, 2012
Acute graft versus host disease after orthotopic liver transplantationInga Mandac Rogulj, Joachim Deeg, Stephanie J Lee
Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti|December 1, 2012
[Wounds in hematology patients]Inga Mandac Rogulj, Ana Planinc Peraica, Slobodanka Ostojić Kolonić
Current Pharmaceutical Design|February 27, 2016
Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic ImplicationsAnna Mies, Ekaterina Bulycheva, Inga Mandac Rogulj, et al.
European Journal of Haematology|June 6, 2019
FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?Vibor Milunović, Karla Mišura Jakobac, Marin Kursar, et al.
Acta Medica Croatica : Casopis Hravatske Akademije Medicinskih Znanosti|November 7, 2012
[Acute renal failure as first manifestation of B-CLL]Inga Mandac Rogulj, Ingrid Prkacin, Mirjana Sabljar-Matovinović, et al.
European Journal of Haematology|January 17, 2016
The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modificationVibor Milunović, Inga Mandac Rogulj, Ana Planinc-Peraica, et al.
Lijecnicki Vjesnik|August 28, 2018
[CURRENT APPROACH TO NON-HODGKIN MANTLE CELL LYMPHOMA: LITERATURE REVIEW]Vibor Milunović, Martina Bogeljić Patekar, Inga Mandac Rogulj, et al.
Croatian Medical Journal|June 13, 2019
Dasatinib-induced nephrotic syndrome: a case of phenoconversionInga Mandac Rogulj, Vid Matišić, Borna Arsov, et al.
Expert Review of Hematology|June 25, 2020
The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?Vibor Milunović, Karla Mišura Jakobac, Inga Mandac Rogulj, et al.
Pageof 2